Neflamapimod is under clinical development by CervoMed and currently in Phase II for Lewy Body Dementia. According to GlobalData, Phase II drugs for Lewy Body Dementia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Neflamapimod LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Neflamapimod overview
Neflamapimod (VX-745) is under development for the treatment of Alzheimer’s disease, Lewy body dementia, cognitive defects in Huntington disease, acute ischemic stroke, forms of frontotemporal dementia and Down syndrome. The drug candidate is administered through oral route as a hard gelatin capsule. It acts by targeting alpha isoform of the protein enzyme p38 mitogen-activated protein kinase (p38 MAPK alpha). It was also under development for the treatment of rheumatoid arthritis.
CervoMed overview
CervoMed, formerly Diffusion Pharmaceuticals Inc, operates as a clinical-stage biotechnology company. It develops standard-of-care therapies. Its products include trans sodium crocetinate and molecule drugs. The company’s novel therapeutics services offer a range of medications tailored to specific medical needs and its Kalydeco is utilized in the treatment of cystic fibrosis; Incivek is prescribed for hepatitis C and Velcade serves as a medication option for individuals with multiple myeloma. CervoMed offers products for cancer, stroke and heart attack. It performs clinical studies on pancreatic cancer and brain metastasis through cancer centers. CervoMed is headquartered in Boston, Massachusetts, the US.
For a complete picture of Neflamapimod’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
